Integrating Polygenic and Monogenic Germline Testing Results Into Prostate Cancer Risk Assessment

Friday, February 22, 2019

4:00am PST

1 hour

C.E.U.: 1 Category 1 Contact Hour

P.A.C.E.: 1 Unit

In this webinar, Dr. Xu will summarize recent data on inherited risk for prostate cancer, including germline mutations in high-penetrance genes (HPGs), risk-associated SNPs, and SNP-based genetic risk score (GRS). He will present detailed data supporting the broad-sense validity of GRS in risk assessment as well the need for assessing the narrow-sense validity of GRS values. Finally, he will review the data supporting the importance of GRS when estimating penetrance of HPGs.

Explore Our Tests Patient Billing Billing CARE

Jianfeng Xu

Speaker

Jianfeng Xu, MD, DrPH is a genomic translational researcher. He was trained in medicine, public health, and genetic epidemiology from Shanghai Medical University in China and the Johns Hopkins University School of Public Health in the U.S.

Dr. Xu’s primary research interests are 1) discovery of genes that are associated with development and progression of diseases, and 2) translation of genomic findings for targeted prevention, screening, and treatment of diseases. Dr. Xu has been a principal investigator for dozens of grants in the U.S. and in China. He and his colleagues discovered multiple genes for cancer and other diseases and published over 400 papers in high impact journals including Science, Nature Genetics, Lancet, and the New England Journal of Medicine.

Dr. Xu developed a genetic risk score (GRS) to measure the cumulative effect of multiple risk-associated variants on disease risk. Since published the GRS method and its application in prostate cancer 10 years ago in the New England Journal of Medicine, he has been working continuously and persistently to improve the GRS method. Currently, the GRS method has been extended to other cancers and diseases to develop personalized disease prevention and early intervention (screening).

Bernard Herrman

Manager, Genomic Science Liaison

Sr. Genetic Specialist, Oncology – Midwest

Mr. Herrman joined Ambry in 2015 and functions as the Oncology Genetic Specialist for the Midwest, providing technical and clinical support, training, and education to current and prospective clients. Mr. Herrman completed his graduate training at the University of Kansas Medical Center, where he earned an M.S. in Molecular Biotechnology and holds a B.S. in Human Biology from the University of Kansas. Prior to his current position with Ambry, Mr. Herrman worked as a Research Associate at the University of Kansas Cancer Center (NCI-CC), focused on the development of a genome-based biomarker assay for early detection and treatment of ovarian cancer and genomic analysis for the discovery of somatic mutations and fusion genes in preeclampsia.